USRE44873E1 - Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof - Google Patents

Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof Download PDF

Info

Publication number
USRE44873E1
USRE44873E1 US13/727,587 US200613727587A USRE44873E US RE44873 E1 USRE44873 E1 US RE44873E1 US 200613727587 A US200613727587 A US 200613727587A US RE44873 E USRE44873 E US RE44873E
Authority
US
United States
Prior art keywords
methyl
imidazole
butyl
carboxylic acid
tetrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US13/727,587
Other languages
English (en)
Inventor
Jianhui Guo
Dong An
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salubris Asset Management Co Ltd
Original Assignee
Salubris Asset Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salubris Asset Management Co Ltd filed Critical Salubris Asset Management Co Ltd
Priority to US13/727,587 priority Critical patent/USRE44873E1/en
Application granted granted Critical
Publication of USRE44873E1 publication Critical patent/USRE44873E1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the invention relates to imidazole-5-carboxylic acid derivatives, their preparation methods and their use as anti-hypertensive drugs.
  • Angiotensin II a main vasoconstrictor hormone of renin-angiotension-aldosterone system (RAAS), plays an important role in pathological physiology of many chronic diseases.
  • the production approach of Angiotensin II which is present in various tissues is mainly as follows: angiotensinogen acted on by renin can be converted to angiotensins I (Ang I) of decapeptide which only has little activity in contraction of blood vessel; and can be further converted by angiotensin converting enzyme to angiotensin II (Ang II) of octapeptide which is the final physiological active substance of renin-angiotension-aldosterone system (RAS) and can induce physiological functions such as contraction of blood vessel and elevation of blood pressure by binding to specific angiotensin II (ATII) receptor.
  • Ang I angiotensins I
  • Ang II angiotensin II
  • ATII specific angiotensin II
  • EP0253310 discloses a series of imidazole derivatives. Research of E. I. Du Pont de Nemours and Company (US) found that a compound of DUP753 has a good effect on lowering blood pressure. It was approved in 1994 and became the first non-peptide type Ang II receptor antagonist, i.e. losartan potassium, which inhibits contraction of blood vessel by selectively blocking the actions of angiotensin II of smooth muscle in blood vessel on its Ang I receptor to achieve the functions of dilating blood vessel and reducing blood pressure.
  • US non-peptide type Ang II receptor antagonist
  • U.S. Pat. No. 5,616,599 discloses a series of 1-biphenylmethylimidazole derivatives whose structures are similar to that of losartan. The significant difference in structure between them is that the chlorine atom at the 4-position of the imidazole ring of losartan is converted to 1-hydroxy-1-methylethyl and the 5-position of that is converted to a carboxyl group, hydroxyl group or pro-drug structures such as ester or amide. It is demonstrated to have good activity in reducing blood pressure. Therefore, Sankyo Company, Ltd. (JP) developed and marketed a drug of olmesartan.
  • JP Sankyo Company, Ltd.
  • losartan Compared with other Ang II receptor antagonists marketed subsequently, losartan has more tolerance, fewer side effects and fewer possibilities to cause cough or edema. Studies have suggested that it is effective for reducing serum uric acid, TC and TG, and has no adverse effect on insulin sensitivity, insulin secretion and glucose tolerance of hyperinsulinism patients and is a safe antihypertensive drug. However, only 14 percent of losartan potassium can be metabolized in vivo to its active substance of EXP3174. Although losartan potassium itself has a strong activity in reducing blood pressure, its activity is only 3 percent of that of EXP3174. Molecular polarity of EXP3174 is too strong to get through the cell membrane by passive absorption forms such as diffusion. It is necessary to change its structure to improve its passive absorption.
  • U.S. Pat. No. 5,298,519 discloses a 5-position carboxyl esterified product of EXP3174, emphasizes on the research of a compound HN-65021, and discloses a test result of lowering blood pressure by oral administration of HN-65021 to show the compound has an activity of lowering blood pressure similar to that of losartan (British Journal of Clinical Pharmacology, 40, 1995, 591-593), it is indicated that converting 5-position carboxyl of the imidazole ring of EXP3174 molecule to a group with a smaller polarity is a tendency of the modification of losartan. It is required to convert the structure of EXP3174 molecule for getting an active compound with a better pharmacological effect of lowering blood pressure.
  • the present invention provides a compound of formula (I), or its pharmaceutically acceptable salts or solvates,
  • R is selected from straight or branched C 1 -C 4 alkyl, or R is
  • R1, R2, and R3 are independently selected from the group consisting of hydrogen, straight or branched C 1 -C 4 alkyl, and C 3 -C 7 cycloalkyl, wherein the alkyl or the cycloalkyl in the definition of R, R1, R2, and R3 is unsubstituted or substituted by 1-3 substituents selected from the group consisting of F, Cl, Br, NH 2 , and OH.
  • R is selected from the group consisting of straight or branched C 1 -C 4 alkyl, and preferably, R is ethyl.
  • R is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • R1 is selected from hydrogen, straight or branched C 1 -C 4 alkyl, and C 3 -C 7 cycloalkyl.
  • R1 is selected from straight or branched C 1 -C 4 alkyl. More preferably, R1 is straight or branched butyl.
  • R is
  • R2 is selected from the group consisting of hydrogen, straight or branched C 1 -C 4 alkyl, and C 3 -C 7 cycloalkyl.
  • R2 is selected from the group consisting of straight or branched C 2 -C 4 alkyl. More preferably, R2 is ethyl, isopropyl, or tert-butyl.
  • R is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • R3 is selected from the group consisting of hydrogen, straight or branched C 1 -C 4 alkyl, and C 3 -C 7 cycloalkyl.
  • R3 is selected from the group consisting of straight or branched C 3 -C 4 alkyl, and C 3 -C 7 cycloalkyl. More preferably, R3 is isopropyl, tert-butyl, or cyclohexyl.
  • the straight or branched C 1 -C 4 alkyl means methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl; preferably methyl, ethyl, propyl, isopropyl, butyl, or tert-butyl.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising 0.05 ⁇ 50 mg of the compound of formula I or its pharmaceutically acceptable salts, and pharmaceutically acceptable carriers, excipients or diluents.
  • the present invention also provides a method of treating a disease, which may be alleviated or cured by inhibiting I receptors of angiotensin II, comprising the step of administrating a patient in need of such treatment with the compound of formula I or its pharmaceutically acceptable salts in the amount of 0.05-30 mg/kg weight/day.
  • the present invention also provides a process for the preparation of the compound of formula I, which includes the following steps:
  • losartan potassium is oxidized to 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]imidazole-5-carboxylic acid;
  • step (b) the oxidative product obtained form step (a) is reacted with triphenylchloromethane to give 2-butyl-4-chloro-1-[2′-(1-triphenylmethyl-tetrazol-5-yl)1,1′-biphenyl-methyl]imidazole-5-carboxylic acid;
  • step (c1) the product obtained from step (b) is reacted with the compounds of formula X—R to give esterified intermediates under alkaline condition; then the trityl is deprotected to obtain compound of formula I in which X is halogen, R represents the following groups:
  • R1, R2, R3 are independently selected from the group consisting of hydrogen, straight or branched, C 1 -C 4 alkyl, and C 3 -C 7 cycloalkyl group.
  • step (c2) when R is selected from the group consisting of straight or branched C 1 -C 4 alkyl, the product obtained from step (b) is reacted under reflux with organic alcohol ROH(R is defined as above) in the presence of catalytic acid to obtain the compound of formula I.
  • the present invention provides a process for the preparation of the compound of formula I.
  • R is selected from straight or branched C 1 -C 4 alkyl
  • the compound can be prepared by the following method:
  • losartan potassium is oxidized to 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]imidazole-5-carboxylic acid in the presence of oxidant such as KMnO 4 :
  • organic alcohol ROH(R is defined as above) and catalytic acid (organic acid such as p-toluenesulfonic acid, or inorganic acid such as hydrochloric acid, sulfuric acid and phosphoric acid) are added, reacted under reflux, extracted and concentrated to obtain the final product.
  • catalytic acid organic acid such as p-toluenesulfonic acid, or inorganic acid such as hydrochloric acid, sulfuric acid and phosphoric acid
  • losartan potassium is oxidized to 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]imidazole-5-carboxylic acid in the presence of oxidant such as KMnO4;
  • step (c) the product from the above step (b) is reacted with the compounds of formula X—R to give esterified intermediates under alkaline condition (such as potassium carbonate and N,N-dimethylacetamide (DME) or N,N-dimethylforamide (DMF)); wherein X is halogen, preferably fluorine, chlorine, bromine.
  • R represents the following structures:
  • R1, R2, and R3 are independently selected from the group consisting of hydrogen, straight or branched C 1 -C 4 alkyl, and C 3 -C 7 cycloalkyl.
  • esterified intermediates from the step (c) are deprotected to remove the triphenylmethyl group in the presence of acids or alcohols (such as methanol, or ethanol) and purified to give the final products.
  • a solvent for the preparation is generally an inert solvent such as water, DMF, or alcohol (such as methanol, ethanol, or isopropanol and the like).
  • the compound obtained according to the method of the invention can be administered to human beings orally, rectally, parenterally (intravenously, intramuscularly or subcutaneously), locally (powders, ointments or drops).
  • Said compound can be administered alone or in combination with other pharmaceutically acceptable compounds.
  • the compounds according to the invention can be administered as a mixture.
  • Solid dosage forms for oral administration may include capsules, tablets, pills, powders and granules.
  • the active compound may be mixed with at least one conventional inert excipients (or carriers) such as citrate sodium, dicalcium phosphate, or with the following components: (a) fillers or compatibilizers, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, amine gum; (c) humectants, for example, glycerin; (d) disintegrants, for example, agar, calcium carbonate, potato starch or cassava starch, alginic acid, some composite silicate and sodium carbonate; (e) slow-dissolving agents, for example, wax, (f) sorbefacients, for example, quaternary ammonium compound; (g) wetting agents,
  • Solid dosage forms such as tablets, rotulas, capsules, pills and granules may be prepared with coatings or shells such as enteric coatings or other materials known by those skilled in the art. They can include opaque agent.
  • active compounds or compounds in the composition can be slow-released in a part of alimentary canal. Examples of embedding components include polymer substance and wax substance. If necessary, the active compounds also can be combined with one or more or excipients above to make a form of micro-capsule.
  • Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures.
  • the liquid dosage form may include inert diluents conventionally used in this field, such as water or other solvents, solubilizing agents and emulsifying agents, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oil, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, caster oil and sesame oil or mixtures or these substances.
  • the composition may also include auxiliary agents such as wetting agents, emulsifying agents and suspending agents, sweetening agents, flavorings and flavors.
  • auxiliary agents such as wetting agents, emulsifying agents and suspending agents, sweetening agents, flavorings and flavors.
  • the suspensions may include suspending agents, for example, ethoxylated isooctadecanol, polyoxyethylene sorbitol, and dehydrated sorbate, microcrystalline cellulose, methanol aluminum and agar or mixtures of these substances.
  • suspending agents for example, ethoxylated isooctadecanol, polyoxyethylene sorbitol, and dehydrated sorbate, microcrystalline cellulose, methanol aluminum and agar or mixtures of these substances.
  • compositions for parenteral injection may include physiologically acceptable sterile solutions, dispersions, suspensions or emulsions with or without water, and sterile powders for reconstituting into sterile injection solutions or dispersions.
  • sterile solutions physiologically acceptable sterile solutions, dispersions, suspensions or emulsions with or without water
  • sterile powders for reconstituting into sterile injection solutions or dispersions sterile injection solutions or dispersions.
  • Appropriate carriers, diluents, solvents or excipients with or without water may include water, ethanol, polyalcohol and appropriate mixtures thereof.
  • Dosage form of the compounds of the invention for local administration may include ointments, powder, sprays and inhalants.
  • the active components is mixed with physiologically acceptable carriers and any antiseptics, buffers, or required propellants if necessary under sterile condition.
  • the term “pharmaceutically acceptable salts” means relatively innocuous inorganic acid addition salts or organic acid addition salts of the compound of the present invention. These salts may be prepared in situ during the final isolation and purification of the compounds; alternatively, prepared by reacting the purified compounds in a form of free alkali with appropriate organic or inorganic acids and separating the salts from the reactants.
  • Representative salts includes hydrobromide, hydrochloride, sulfate, sulphite, acetate, oxalate, pentanoate, oleate, palmate, stearate, laurate, borate, benzoate, lactate, phosphate, toluene formate, citrate, maleate, fumarate, succinate, tartrate, benzoate, methanesulfonate, gluconate, lactobionate and dodecylsulfonate and the like.
  • They may contain cations based on alkali metals and alkali-earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, and cations of innocuous amine, quarternary amine, and amine cations, including but not limited to amine, tetramethyl amine, tetraethyl amine, methyl amine, dimethyl amine, trimethyl amine, tri-ethylamine, ethylamine and the like.
  • alkali metals and alkali-earth metals such as sodium, lithium, potassium, calcium, magnesium and the like
  • cations of innocuous amine, quarternary amine, and amine cations including but not limited to amine, tetramethyl amine, tetraethyl amine, methyl amine, dimethyl amine, trimethyl amine, tri-ethylamine, ethylamine and the like.
  • the compounds in accordance with the present invention have an effect of lowering blood pressure, and can be used for preparation of medicines to treat high blood pressure.
  • the effect for lowering blood pressure of the compounds of the invention may be determined by conventional methods. A preferred evaluating method is described as follow:
  • a female spontaneously hypertensive rat is anaesthetize by abdominal cavity injection with diazepam of 5 mg/kg and ketamine hydrochloride of 50 mg/kg and its back is fixed.
  • An artery conduit is inserted from the left of a femoral artery to a lower abdominal aorta, and then a stomach fistula treatment is operated. After 20-30 hours for postoperative recovery, the artery conduit is connected to a pressure transducer by a perfusion three-way tube. Blood pressure signals per pulse are transformed into biologic signals by the pressure transducer, and systolic blood pressures and diastolic blood pressures per pulse are real-time recorded by a computer.
  • the present invention has the following advantage: compared with the conventional Ang II receptor antagonists, the compounds of the invention have low toxicity and high efficiency of conversion with an equal effect of lowering blood pressure.
  • a female spontaneously hypertensive rat is anaesthetize by abdominal cavity injection with diazepam of 5 mg/kg and ketamine hydrochloride of 50 mg/kg and its back is fixed.
  • An artery conduit is inserted from the left of a femoral artery to a lower abdominal aorta, and than a stomach fistula treatment is operated. After 20-30 hours for postoperative recovery, the artery conduit is connected to it pressure transducer by a perfusion three-way tube. Blood pressure signals per pulse are transformed into biologic signals by pressure transducer, and systolic blood pressures and diastolic blood pressures per pulse are real-time recorded by a computer.
  • the SD rats are orally administrated by intragastric infusion with a dosage of 20 mg/kg.
  • Blood samples are collected from an orbit at the time of 3 hours since the administration.
  • the blood samples freely drop into centrifuge tubes.
  • the sampling amount of blood is 0.3 ⁇ 0.5 ml, and the blood plasma is centrifugalized.
  • the blood is analyzed by using HPLC method to get the amount of EXP3174 in the blood plasma. Based on the molar ratio of the amount of EXP3174 and the amount of administration dosage, a ratio of the experiment compounds being converted into active metabolite in vivo may be calculated.
  • mice with weight of 18-22 g are randomly divided into two groups, each group including 10 ones with two identical halves for male and female. The mice are fasted for 6 hours, and then the two groups of mice are administrated by intragastric infusion with the compounds of the present invention in the amount of 10 g/kg, 5 g/kg, 2 g/kg.
  • the administration volume is 0.8 ml/20 g, and the solvent is 0.5% CMC-Na. Observe and accumulate the number of dead animals during 14 days after administration (one administration) to calculate LD50.
  • the compared data is as follows:
  • the compounds of the invention Compared with the conventional Ang II receptor antagonists, the compounds of the invention have low toxicity and high efficiency of conversion with an equal effect of lowering blood pressure.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
US13/727,587 2006-02-20 2006-07-31 Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof Active USRE44873E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/727,587 USRE44873E1 (en) 2006-02-20 2006-07-31 Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN200610023991 2006-02-20
CNA2006100239910A CN101024643A (zh) 2006-02-20 2006-02-20 咪唑－5－羧酸类衍生物、制备方法及其应用
US11/576,094 US7858651B2 (en) 2006-02-20 2006-07-31 Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof
US13/727,587 USRE44873E1 (en) 2006-02-20 2006-07-31 Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof
PCT/CN2006/001914 WO2007095789A1 (fr) 2006-02-20 2006-07-31 Dérivés d'acide imidazol-5-carboxylique, leurs procédés de préparation et leur utilisation

Publications (1)

Publication Number Publication Date
USRE44873E1 true USRE44873E1 (en) 2014-04-29

Family

ID=38436915

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/727,587 Active USRE44873E1 (en) 2006-02-20 2006-07-31 Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof
US11/576,094 Active US7858651B2 (en) 2006-02-20 2006-07-31 Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/576,094 Active US7858651B2 (en) 2006-02-20 2006-07-31 Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof

Country Status (12)

Country Link
US (2) USRE44873E1 (ja)
EP (1) EP1988090B1 (ja)
JP (1) JP5250760B2 (ja)
KR (1) KR101179110B1 (ja)
CN (2) CN101024643A (ja)
AU (1) AU2006338796B2 (ja)
CA (1) CA2643005C (ja)
DK (1) DK1988090T3 (ja)
ES (1) ES2424154T3 (ja)
PL (1) PL1988090T3 (ja)
PT (1) PT1988090E (ja)
WO (1) WO2007095789A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
CA2671816C (en) * 2006-12-06 2012-06-05 Shanghai Allist Pharmaceutical., Inc. Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101317842A (zh) * 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
AU2009246670A1 (en) * 2008-05-15 2009-11-19 Merck Sharp & Dohme Corp. Angiotensin II receptor antagonists
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
JP5575783B2 (ja) * 2008-12-12 2014-08-20 ファーマコステック カンパニー リミテッド トリフェニルメタン保護基の除去方法
KR101213467B1 (ko) * 2010-04-30 2012-12-20 진양제약주식회사 로자탄 대사체 이엑스피-3174 이수화물의 신규한 제조 방법
CN103012377A (zh) * 2011-09-27 2013-04-03 江苏艾力斯生物医药有限公司 一种咪唑-5-羧酸酯的重结晶方法
CN102558064B (zh) * 2012-01-29 2014-04-16 安润医药科技（苏州）有限公司 抗高血压化合物及其制备方法和应用，以及其在药学上可接受的盐
CN109320501B (zh) 2013-11-01 2021-06-01 深圳信立泰药业股份有限公司 阿利沙坦酯无定形及其制备方法及含所述无定形的药物组合物
CN103965171A (zh) * 2014-04-30 2014-08-06 上海艾力斯医药科技有限公司 一种阿利沙坦酯的制备方法
CN106188012B (zh) * 2014-06-20 2018-11-30 深圳信立泰药业股份有限公司 一种阿利沙坦酯结晶及其制备方法及含有该结晶的药物组合物
CN105218527B (zh) * 2015-10-10 2018-04-24 江苏宝众宝达药业有限公司 一种exp-3174的制备方法
AU2017209250B2 (en) 2016-01-20 2021-07-29 Shenzhen Salubris Pharmaceuticals Co. Ltd Angiotensin II receptor antagonist metabolite and NEP inhibitor composite, and preparation method thereof

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253310A2 (en) 1986-07-11 1988-01-20 E.I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
EP0535420A1 (de) 1991-10-04 1993-04-07 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Acylale von Imidazol-5-carbonsäurederivaten, als Angiotensin II Inhibitoren
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
WO2005011646A2 (en) 2003-07-31 2005-02-10 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
WO2005023182A2 (en) 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006115187A1 (ja) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited 骨代謝性疾患の予防又は治療のための医薬
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
WO2008067687A1 (fr) 2006-12-06 2008-06-12 Shanghai Allist Pharmaceutical., Inc. Sels de dérivés d'acide imidazol-5-carboxylique, procédés de préparation et utilisation
EP2116242A1 (en) 2007-01-05 2009-11-11 Shanghai Allist Pharmaceuticals, Inc. New pharmaceutical composition
US20100168193A1 (en) 2007-06-07 2010-07-01 Shanghai Allist Pharmaceuticals, Inc. Therapeutic use of imidazole-5-carboxylic acid derivatives
US20100292286A1 (en) 2007-10-11 2010-11-18 Jianhui Guo Crystalline imidazole-5-carboxylic acid derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199548T1 (de) * 1992-06-02 2001-03-15 Sankyo Co 4-carboxyimidazolderivate als angiotensin-ii- antagonisten und ihre therapeutische verwendung
JPH083162A (ja) * 1994-04-19 1996-01-09 Tanabe Seiyaku Co Ltd イミダゾピリジン誘導体及びその製法
WO1996040257A1 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
EP0253310A2 (en) 1986-07-11 1988-01-20 E.I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
EP0535420A1 (de) 1991-10-04 1993-04-07 Chemisch Pharmazeutische Forschungsgesellschaft m.b.H. Acylale von Imidazol-5-carbonsäurederivaten, als Angiotensin II Inhibitoren
US5298519A (en) 1991-10-04 1994-03-29 Chemish Pharmazeutische Forschungsgesellschaft M.B.H. Acylals of imidazole-5-carboxylic acid derivatives, and their use as angiotensin (II) inhibitors
CN1071426A (zh) 1991-10-04 1993-04-28 化学药物研究股份公司 咪唑-5-羧酸衍生物的新的缩醛的制备方法
WO2005011646A2 (en) 2003-07-31 2005-02-10 Nicox S.A. Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases
WO2005023182A2 (en) 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
WO2006115187A1 (ja) 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited 骨代謝性疾患の予防又は治療のための医薬
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
WO2007095789A1 (fr) 2006-02-20 2007-08-30 Shanghai Allist Pharmaceutical., Inc. Dérivés d'acide imidazol-5-carboxylique, leurs procédés de préparation et leur utilisation
US7858651B2 (en) 2006-02-20 2010-12-28 Shanghai Allist Pharmaceutical, Inc. Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof
EP1988090A1 (en) 2006-02-20 2008-11-05 Shanghai Allist Pharmaceutical., Inc. Imidazol-5-carboxylic acid derivatives, preparation methods and use therrof
US20090036505A1 (en) 2006-02-20 2009-02-05 Jianhui Guo Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof
WO2008067687A1 (fr) 2006-12-06 2008-06-12 Shanghai Allist Pharmaceutical., Inc. Sels de dérivés d'acide imidazol-5-carboxylique, procédés de préparation et utilisation
US20090326024A1 (en) 2006-12-06 2009-12-31 Jianhui Guo Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
EP2103610A1 (en) 2006-12-06 2009-09-23 Shanghai Allist Pharmaceutical., Inc. The salts of imidazol-5-carboxylic acid derivatives, preparation methods and use therrof
US7943648B2 (en) 2006-12-06 2011-05-17 Shanghai Allist Pharmaceutical Inc. Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
EP2116242A1 (en) 2007-01-05 2009-11-11 Shanghai Allist Pharmaceuticals, Inc. New pharmaceutical composition
US20090326025A1 (en) 2007-01-05 2009-12-31 Lu Yaoru New pharmaceutical composition
US8138214B2 (en) 2007-01-05 2012-03-20 Shanghai Allist Pharmaceutical, Inc. Pharmaceutical composition
US20100168193A1 (en) 2007-06-07 2010-07-01 Shanghai Allist Pharmaceuticals, Inc. Therapeutic use of imidazole-5-carboxylic acid derivatives
US20100292286A1 (en) 2007-10-11 2010-11-18 Jianhui Guo Crystalline imidazole-5-carboxylic acid derivative
US8178569B2 (en) 2007-10-11 2012-05-15 Shanghai Allist Pharmaceuticals, Inc. Crystalline imidazole-5-carboxylic acid derivative

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
A.M. Rouhi, Chem. & Eng. News, Feb. 24, 2003, 81(8), 32-35. *
Aug. 1, 2011 USPTO Notice "Clarification of Criteria for Reissue Error in View of In re Tanaka".
Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 1, P69-74, Elizabeth M. Naylor et al., "Potent Imidazole Angiotension II Antagonists: Acyl Sulfonamides and Acyl Sulfinamides as Tetrazole Replacements", (1994).
Byrn et al. Solid-State Chemistry of Drugs, 2d, Chapter 11 Hydrates and Solvates, 233-247 (1999). *
Dahlof, B., End-Organ Damage: does it really matter how we prevent it? (2003), European Heart Journal Supplements 5 (Supplement F), pp. F33-F39.
Drugs of the Future, 1996, vol. 21, No. 2, P139-142, Mealy, N. 35 al., "Elisartan Potassium. Antihypertensive angiotensin II antagonist, HN-6502 1".
Grandi A.M., et al., Blockade of the renin-angiotensin-aldosterone system: effects on hypertensive target organ damage (2006), vol. 4, Cardiovascular and Hematological Agents in Medicinal Chemistry, pp. 219-228.
Harwood et al. "Experimental Organic Chemistry, Standard and Microscale", Blackwell Science Ltd. p. 131 (1999).
International Search Report and Written Opinion for corresponding PCT application No. PCT/CN2008/001715, date of mailing Jan. 22, 2009.
International Search Report issued in PCT/CN2008/000048, dated Apr. 17, 2008.
International Search Report of PCT/CN2006/003301, dated Jun. 28, 2007.
Ma, et al., "Effects of Losartan on Cardiac and Renal Functions in Elderly Hypertensive Patients", Journal of Jilin University (Medicine Edition), vol. 31, 2005, pp. 620-622.
Mealy et al., "Elisartan Potassium. Antihypertensive Angiotensin II Antagonist," Drugs of the Future. vol. 21, No. 2, 1996, pp. 139-142.
Morisette et al. Adv. Drug Delivery Rev. 56, 275-300 (2004). *
Naylor et al., "Potent imidazole angiotensin II antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements," Bioorganic & Medicinal Chemistry Letters, vol. 4, No. 1, P69-74, (1994).
Notice of Allowance dated Jul. 9, 2012, U.S. Application No. 12/663,183.
Supplementary European Search Report corresponding to European Application No. 08038798 dated Nov. 30, 2010.
Wolf, S., et al., Sind alle Antihypertensiva nephroprotektiv? (2004), Herz 29, Nr. 3, pp. 248-254.

Also Published As

Publication number Publication date
WO2007095789A1 (fr) 2007-08-30
PT1988090E (pt) 2013-08-05
CN100506818C (zh) 2009-07-01
CA2643005C (en) 2012-05-15
EP1988090B1 (en) 2013-05-01
KR101179110B1 (ko) 2012-09-07
KR20080096707A (ko) 2008-10-31
AU2006338796A1 (en) 2007-08-30
CN101024643A (zh) 2007-08-29
ES2424154T3 (es) 2013-09-27
US7858651B2 (en) 2010-12-28
JP5250760B2 (ja) 2013-07-31
CA2643005A1 (en) 2007-08-30
EP1988090A4 (en) 2010-06-30
PL1988090T3 (pl) 2013-10-31
AU2006338796B2 (en) 2011-05-12
CN101031562A (zh) 2007-09-05
JP2009527509A (ja) 2009-07-30
US20090036505A1 (en) 2009-02-05
DK1988090T3 (da) 2013-08-05
EP1988090A1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
USRE44873E1 (en) Imidazole-5-carboxylic acid derivatives, the preparation method therefor and the uses thereof
EP0459136B1 (en) Benzimidazole derivatives, their production and use
CA2036304C (en) Pyrimidinedione derivatives, their production and use
US7943648B2 (en) Salts of imidazole-5-carboxylic acid derivatives, a method for preparing same and pharmaceutical compositions comprising same
JP2009527509A5 (ja)
EP0539509B1 (en) 4-alkylimidazole derivatives
US20060252939A1 (en) Preparation of candesartan cilexetil
DE60304175T2 (de) Verfahren zur herstellung von losartan und losartan-kaliumsalz
CA2469656A1 (en) Amorphous form of 2-n-butyl-3-( (2-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl) methyl) -1,3-diazaspiro (4,4') non-1-en-4-one
KR20100110438A (ko) 올메살탄의 신규한 에스테르 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
KR980009263A (ko) 벤조푸란계 치환기를 갖는 피리딜 이미다졸 유도체, 그의 제조방법 및 그를 함유하는 혈압 하제
JPH07188171A (ja) １、２−ジヒドロ−２−オキソ−３−メチルスルホニルアミノメチルピリジン
EP1634880A2 (en) Processes for preparing losartan and losartan potassium
IE83797B1 (en) Benzimidazole derivatives, their production and use and use as angiotensin II antagonists

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552)

Year of fee payment: 8

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12